DK169340B1 - Analogifremgangsmåde til fremstilling af nitrosoureaderivater - Google Patents
Analogifremgangsmåde til fremstilling af nitrosoureaderivater Download PDFInfo
- Publication number
- DK169340B1 DK169340B1 DK524283A DK524283A DK169340B1 DK 169340 B1 DK169340 B1 DK 169340B1 DK 524283 A DK524283 A DK 524283A DK 524283 A DK524283 A DK 524283A DK 169340 B1 DK169340 B1 DK 169340B1
- Authority
- DK
- Denmark
- Prior art keywords
- formula
- derivatives
- chloroethyl
- animals
- preparation
- Prior art date
Links
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical class NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 title claims abstract description 7
- 238000000034 method Methods 0.000 title claims description 35
- 230000008569 process Effects 0.000 title claims description 12
- 238000002360 preparation method Methods 0.000 title claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 6
- 239000001257 hydrogen Substances 0.000 claims abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract 2
- 125000001544 thienyl group Chemical group 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 41
- 241001465754 Metazoa Species 0.000 claims description 18
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 16
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 10
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 5
- 235000019253 formic acid Nutrition 0.000 claims description 5
- 238000011081 inoculation Methods 0.000 claims description 5
- 235000010288 sodium nitrite Nutrition 0.000 claims description 5
- 239000004157 Nitrosyl chloride Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000000018 nitroso group Chemical group N(=O)* 0.000 claims description 4
- VPCDQGACGWYTMC-UHFFFAOYSA-N nitrosyl chloride Chemical compound ClN=O VPCDQGACGWYTMC-UHFFFAOYSA-N 0.000 claims description 4
- 235000019392 nitrosyl chloride Nutrition 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- BCMYXYHEMGPZJN-UHFFFAOYSA-N 1-chloro-2-isocyanatoethane Chemical compound ClCCN=C=O BCMYXYHEMGPZJN-UHFFFAOYSA-N 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 150000007529 inorganic bases Chemical class 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000007945 N-acyl ureas Chemical class 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 150000003672 ureas Chemical class 0.000 description 3
- OGBVRMYSNSKIEF-UHFFFAOYSA-N Benzylphosphonic acid Chemical compound OP(O)(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-N 0.000 description 2
- 102100021906 Cyclin-O Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- -1 Methyl CCNU Chemical compound 0.000 description 2
- JWOLLWQJKQOEOL-UHFFFAOYSA-N OOOOOOOOOOOOO Chemical compound OOOOOOOOOOOOO JWOLLWQJKQOEOL-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- UIQSKEDQPSEGAU-UHFFFAOYSA-N 1-Aminoethylphosphonic Acid Chemical compound CC(N)P(O)(O)=O UIQSKEDQPSEGAU-UHFFFAOYSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- AATNZNJRDOVKDD-UHFFFAOYSA-N 1-[ethoxy(ethyl)phosphoryl]oxyethane Chemical compound CCOP(=O)(CC)OCC AATNZNJRDOVKDD-UHFFFAOYSA-N 0.000 description 1
- ZKFNOUUKULVDOB-UHFFFAOYSA-N 1-amino-1-phenylmethyl phosphonic acid Chemical compound OP(=O)(O)C(N)C1=CC=CC=C1 ZKFNOUUKULVDOB-UHFFFAOYSA-N 0.000 description 1
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 1
- VGUWZCUCNQXGBU-UHFFFAOYSA-N 3-[(4-methylpiperazin-1-yl)methyl]-5-nitro-1h-indole Chemical compound C1CN(C)CCN1CC1=CNC2=CC=C([N+]([O-])=O)C=C12 VGUWZCUCNQXGBU-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 208000007093 Leukemia L1210 Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- DTAFLBZLAZYRDX-UHFFFAOYSA-N OOOOOO Chemical compound OOOOOO DTAFLBZLAZYRDX-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- KVEBNTWOYMYORY-UHFFFAOYSA-N diethoxyphosphoryl(phenyl)methanamine Chemical compound CCOP(=O)(OCC)C(N)C1=CC=CC=C1 KVEBNTWOYMYORY-UHFFFAOYSA-N 0.000 description 1
- AIPRAPZUGUTQKX-UHFFFAOYSA-N diethoxyphosphorylmethylbenzene Chemical compound CCOP(=O)(OCC)CC1=CC=CC=C1 AIPRAPZUGUTQKX-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- GATNOFPXSDHULC-UHFFFAOYSA-N ethylphosphonic acid Chemical compound CCP(O)(O)=O GATNOFPXSDHULC-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- KEBHLNDPKPIPLI-UHFFFAOYSA-N hydron;2-(3h-inden-4-yloxymethyl)morpholine;chloride Chemical compound Cl.C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 KEBHLNDPKPIPLI-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 238000011670 long-evans rat Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8219199A FR2536075B1 (fr) | 1982-11-17 | 1982-11-17 | Nouveaux derives de la nitrosouree, leur procede de preparation et les compositions pharmaceutiques les renfermant |
FR8219199 | 1982-11-17 |
Publications (3)
Publication Number | Publication Date |
---|---|
DK524283D0 DK524283D0 (da) | 1983-11-16 |
DK524283A DK524283A (da) | 1984-05-18 |
DK169340B1 true DK169340B1 (da) | 1994-10-10 |
Family
ID=9279241
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK524283A DK169340B1 (da) | 1982-11-17 | 1983-11-16 | Analogifremgangsmåde til fremstilling af nitrosoureaderivater |
Country Status (19)
Country | Link |
---|---|
US (1) | US4567169A (de) |
EP (1) | EP0117959B1 (de) |
JP (1) | JPS59106497A (de) |
AT (1) | ATE21905T1 (de) |
AU (1) | AU557139B2 (de) |
CA (1) | CA1204442A (de) |
DE (1) | DE3365900D1 (de) |
DK (1) | DK169340B1 (de) |
ES (1) | ES8501772A1 (de) |
FR (1) | FR2536075B1 (de) |
IE (1) | IE56259B1 (de) |
IL (1) | IL70253A (de) |
MA (1) | MA19952A1 (de) |
NO (1) | NO163409C (de) |
NZ (1) | NZ206293A (de) |
OA (1) | OA07589A (de) |
PT (1) | PT77666B (de) |
SU (1) | SU1303024A3 (de) |
ZA (1) | ZA838558B (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2567129B1 (fr) * | 1984-07-06 | 1986-12-05 | Adir | Nouveaux derives de l'oxaazaphosphorine, leur procede de preparation et les compositions pharmaceutiques les renfermant |
IT1246778B (it) * | 1991-04-12 | 1994-11-26 | Boehringer Mannheim Italia | Nitrosocarbamoil derivati di acidi gem-difosfonici, un processo per la loro preparazione e composizioni farmaceutiche che li contengono |
US5298499A (en) * | 1991-07-05 | 1994-03-29 | Research Triangle Institute | S-2-(substituted ethylamino)ethyl phosphorothioates |
WO1997018819A1 (en) * | 1995-11-20 | 1997-05-29 | Sepracor, Inc. | Antineoplastic methods and compositions employing optically pure (-)-fotemustine |
JP2000500495A (ja) * | 1995-11-20 | 2000-01-18 | セプラコール,インク. | (+)−フォテムスチンを用いる新生物を治療するための方法および組成物 |
US20040072889A1 (en) * | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
CN100365002C (zh) * | 2004-06-02 | 2008-01-30 | 上海医药科技发展有限公司 | 注射用福莫司汀制备工艺 |
AT501496B1 (de) * | 2005-02-21 | 2007-03-15 | Iep Gmbh | Verfahren zur enantioselektiven enzymatischen reduktion von ketoverbindungen |
CN102311456A (zh) * | 2011-07-08 | 2012-01-11 | 山东睿鹰先锋制药有限公司 | 一种福莫司汀原料药的合成方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3920733A (en) * | 1973-08-06 | 1975-11-18 | Monsanto Co | Ureidoalkylphosphonic acids |
-
1982
- 1982-11-17 FR FR8219199A patent/FR2536075B1/fr not_active Expired
-
1983
- 1983-11-02 US US06/547,881 patent/US4567169A/en not_active Expired - Lifetime
- 1983-11-15 PT PT77666A patent/PT77666B/pt unknown
- 1983-11-16 ZA ZA838558A patent/ZA838558B/xx unknown
- 1983-11-16 IL IL70253A patent/IL70253A/xx not_active IP Right Cessation
- 1983-11-16 EP EP83402209A patent/EP0117959B1/de not_active Expired
- 1983-11-16 AT AT83402209T patent/ATE21905T1/de active
- 1983-11-16 CA CA000441305A patent/CA1204442A/fr not_active Expired
- 1983-11-16 MA MA20173A patent/MA19952A1/fr unknown
- 1983-11-16 DK DK524283A patent/DK169340B1/da not_active IP Right Cessation
- 1983-11-16 NZ NZ206293A patent/NZ206293A/en unknown
- 1983-11-16 DE DE8383402209T patent/DE3365900D1/de not_active Expired
- 1983-11-16 NO NO834214A patent/NO163409C/no unknown
- 1983-11-16 AU AU21436/83A patent/AU557139B2/en not_active Expired
- 1983-11-16 IE IE2680/83A patent/IE56259B1/en not_active IP Right Cessation
- 1983-11-16 SU SU833665922A patent/SU1303024A3/ru active
- 1983-11-17 ES ES527353A patent/ES8501772A1/es not_active Expired
- 1983-11-17 JP JP58217066A patent/JPS59106497A/ja active Granted
- 1983-11-17 OA OA58159A patent/OA07589A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
FR2536075A1 (fr) | 1984-05-18 |
ES527353A0 (es) | 1984-12-01 |
CA1204442A (fr) | 1986-05-13 |
EP0117959B1 (de) | 1986-09-03 |
NZ206293A (en) | 1987-02-20 |
IL70253A (en) | 1986-10-31 |
NO163409C (no) | 1990-05-23 |
NO163409B (no) | 1990-02-12 |
AU2143683A (en) | 1984-05-24 |
FR2536075B1 (fr) | 1985-07-05 |
OA07589A (fr) | 1985-03-31 |
JPS6411637B2 (de) | 1989-02-27 |
IE56259B1 (en) | 1991-06-05 |
SU1303024A3 (ru) | 1987-04-07 |
EP0117959A2 (de) | 1984-09-12 |
ATE21905T1 (de) | 1986-09-15 |
EP0117959A3 (en) | 1984-11-14 |
PT77666A (fr) | 1983-12-01 |
AU557139B2 (en) | 1986-12-04 |
DK524283A (da) | 1984-05-18 |
DK524283D0 (da) | 1983-11-16 |
MA19952A1 (fr) | 1984-07-01 |
JPS59106497A (ja) | 1984-06-20 |
IE832680L (en) | 1984-05-17 |
IL70253A0 (en) | 1984-02-29 |
ES8501772A1 (es) | 1984-12-01 |
ZA838558B (en) | 1984-07-25 |
NO834214L (no) | 1984-05-18 |
US4567169A (en) | 1986-01-28 |
DE3365900D1 (en) | 1986-10-09 |
PT77666B (fr) | 1986-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6680308B1 (en) | Use of organophosphorus compounds for the therapeutic and prophylactic treatment of infections | |
US5098892A (en) | Process for preparation of bicyclic compounds | |
DK169340B1 (da) | Analogifremgangsmåde til fremstilling af nitrosoureaderivater | |
EP2240501B1 (de) | Hydroxy-bisphosphonsäurederivate als auf knochengewebe gerichtete vektoren | |
CN103420942A (zh) | 对乙、丁酰胆碱酯酶具有双重抑制活性化合物 | |
JP2002520419A (ja) | リン有機化合物およびその使用 | |
CN112047944A (zh) | 一种选择性抑制激酶化合物及其用途 | |
KR100396036B1 (ko) | 골다공증 치료를 위한 디포스폰산 염 | |
US6753324B2 (en) | Phosphorous organic compounds and their use | |
DK155520B (da) | Analogifremgangsmaade til fremstilling af aminosyrederivater eller fysiologisk acceptable salte deraf | |
JP2002533350A (ja) | 有機燐化合物、及びそれらの使用 | |
JP3045354B2 (ja) | チオキサンテノン類およびその抗腫瘍剤 | |
HU218783B (hu) | Eljárás foszfolipidszármazékok és e vegyületeket tartalmazó gyógyszerkészítmények előállítására | |
PT93675B (pt) | Processo para a preparacao de derivados de acidos aminodicarboxilicos insaturados, contendo fosforo | |
HU194213B (en) | Process for production of 3-alkoxi-2-n-pirrolidin-n-piridil-n-furil /or n-tienil/-methil-prophil amins | |
Musson et al. | Synthetic and preliminary hemodynamic and whole animal toxicity studies on (R, S)-,(R)-, and (S)-2-methyl-3-(2, 4, 5-trihydroxyphenyl) alanine | |
JP2825643B2 (ja) | 新規アリールオキシーアルキルアミン、その製法及びこれを含有する心臓循環系疾患治療用の医薬品 | |
JPS58146564A (ja) | 4−ジフエニルメチル−1−〔(オキソアルキル)イミノ〕メチル−ピペリジン類およびそれらの誘導体類 | |
HU208144B (en) | Process for producing 2-formyl-benzyl-phosphonic acid derivatives and antiviral pharmaceutical compositions comprising such compounds | |
KR20220163465A (ko) | 엔테카비르 모노포스페이트 알라닌아미드 페놀 에스테르 및 이의 의약적 용도 | |
DK200200115U3 (da) | Hidtil ukendte salte af 4-amino-1-hydroxybutyliden-1, 1-bisphosphonsyre, deres fremstilling og anvendelse | |
FI117053B (fi) | Pyridyylibisfosfonaatit käytettäväksi terapeuttisena aineena | |
KR0165936B1 (ko) | 메틸-5-하이드록시-디나프토[1,2-2',3']-푸란-7,12-디온-6-카복실레이트 및 그의 알칼리 금속염을 유효성분으로 함유하는 항폴리오바이러스용 약제 조성물 | |
IE60110B1 (en) | 2,5-Pyrrolidinedione derivatives useful as antiarrhythmic agents | |
JPS6056943A (ja) | アセチレン誘導体、その製造方法およびこれを含有する医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B1 | Patent granted (law 1993) | ||
PUP | Patent expired |